Cargando…
The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
We evaluated glaucoma patients for the efficacy, safety and satisfaction associated with switching from brinzolamide 1% and brimonidine 0.1% to a fixed combination of brinzolamide 1% and brimonidine 0.1%. A total of 22 glaucoma patients were enrolled and completed this prospective, nonrandomized stu...
Autores principales: | Onoe, Hiromitsu, Hirooka, Kazuyuki, Nagayama, Mikio, Hirota, Atsushi, Mochizuki, Hideki, Sagara, Takeshi, Suzuki, Katsuyoshi, Okumichi, Hideaki, Kiuchi, Yoshiaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622027/ https://www.ncbi.nlm.nih.gov/pubmed/34830510 http://dx.doi.org/10.3390/jcm10225228 |
Ejemplares similares
-
The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients
por: Onoe, Hiromitsu, et al.
Publicado: (2022) -
Ocular Distribution of Brimonidine and Brinzolamide after Topical Instillation of a 0.1% Brimonidine Tartrate and 1% Brinzolamide Fixed-Combination Ophthalmic Suspension: An Interventional Study
por: Orii, Yusuke, et al.
Publicado: (2023) -
Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension
por: Gandolfi, Stefano A., et al.
Publicado: (2014) -
Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension
por: Whitson, Jess T, et al.
Publicado: (2013) -
Efficacy and safety of a fixed combination of 1% brinzolamide and 0.1% brimonidine as treatment for glaucoma: a retrospective study focusing on the number of ingredients
por: Aoki, Ryota, et al.
Publicado: (2022)